Latest News

RCA's first State of Retina Care report surveys 115+ affiliated specialists on access, practice pressures, and clinical research.

The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Q3 2026 delivered advances in some closely watched pipeline products.

After four years and 500+ office-based procedures, Johnathan Feistmann, MD, shares how the model shortened time to surgery for fovea-threatening cases while reshaping patient experience and practice workflow.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

Influence on effective lens position in cataract and lens-based surgery.

Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.

Bausch + Lomb's SeeLyra femtosecond laser platform, featuring live OCT imaging, has received CE mark approval for cataract, LASIK, and corneal procedures in Europe.

Majda Hadziahmetovic, MD, on MacTel neovascular warning signs, urgent referral, and how Encelto reshapes screening.

AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.